CompletedNot Applicable

Predictive Model for High-Flow Nasal Cannula Failure in COVID-19-related Acute Hypoxemic Respiratory Failure Based on Metabolomics and Clinical Data

Spain111 participantsStarted 2020-03-01

Plain-language summary

The aim of this prospective observational cohort study is to develop a predictive model for high-flow nasal cannula (HFNC) failure in patients with acute hypoxemic respiratory failure (AHRF) caused by SARS-CoV-2. By combining clinical data and metabolomic profiles, the study seeks to answer: \- Can integrating clinical parameters with metabolomic markers enhance the prediction of HFNC failure in AHRF patients? Participants with AHRF due to SARS-CoV-2 receiving HFNC under standard-of-care protocols will be monitored until hospital discharge or death. Blood samples for metabolomic analysis will be collected at inclusion.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients (≥18 years old) with acute hypoxemic respiratory failure (AHRF) confirmed as secondary to SARS-CoV-2 infection via PCR testing. * Requirement for high-flow nasal cannula (HFNC) initiated within 48 hours of hospital admission. Exclusion Criteria: * Patients under the age of 18 * Patients with active "do not resuscitate" (DNR) orders at the time of inclusion.

What they're measuring

Predictive Model Development

Timeframe: From the initiation of HFNC until the need for intubation, hospital discharge, or death, whichever occurs first (up to 28 days). Completed using the Training Cohort (March 2020 to April 2021).

Trial details

NCT IDNCT06695442

SponsorHospital del Mar Research Institute (IMIM)

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-09-30

View on ClinicalTrials.gov More Acute Hypoxemic Respiratory Failure trials